Anixa Biosciences has announced encouraging updated survival data from its ongoing Phase 1 clinical trial of lira-cel, a CAR-T cell therapy designed to target recurrent ovarian cancer. This early-stag

Breast cancer vaccine final Phase 1 data shows all primary endpoints were met and protocol-defined immune responses in 74% of participants—Phase 2 preparations ongoing Ovarian cancer CAR-T therapy, lira-cel, advances to highest dose level to date in fifth cohort with lymphodepletion—four...

Breast cancer vaccine final Phase 1 data shows all primary endpoints were met and protocol-defined immune responses in 74% of participants—Phase 2 preparations ongoing Ovarian cancer CAR-T therapy, lira-cel, advances to highest dose level to date in fifth cohort with lymphodepletion—four patients surpass one year of survival, longest at approximately 28 months Presentation to highlight …

8 bin lira karşılığında 12 bebeğin ölümüne neden olan yenidoğan çetesinden tutuksuz sanık Dr. Seyhmus Çelik, savunmasında kan donduran itiraflarda bulundu. Kalp hastası bir bebeğin ölümünü anlatan Çel...

Reported Monday, May 11 - 8:59am EDT (TheFly subscription required to read more.)

Anixa Biosciences has reported promising survival outcomes from its Phase 1 trial of Lira-cel, a CAR-T therapy for recurrent ovarian cancer. The findings raise hope for patients with limited treatment options.

Anixa Biosciences, a biotech firm focused on cancer treatment, will present at the Water Tower Research Insights Conference on April 14, 2026.

Anixa Biosciences has revealed that Dr. Jose Conejo-Garcia will be the keynote speaker at the upcoming South Carolina Clinical & Translational Research Institute Retreat, focused on innovative therapies.

Anixa Biosciences (NASDAQ: ANIX) will present two clinical-stage immunotherapy programs at the New York Academy of Sciences' Frontiers in Cancer Immunotherapy symposium on June 22–23, 2026.Presentations cover the Phase 1 ovarian cancer CAR‑T therapy lira‑cel and a breast cancer vaccine with all major primary endpoints met and protocol-defined immune responses in 74% of participants.

Anixa Biosciences (NASDAQ: ANIX) reported updated survival and safety observations from its ongoing Phase 1 trial of lira-cel, a CAR-T therapy for recurrent ovarian cancer.Multiple patients have lived well beyond the typical three‑to‑four‑month median survival, and preliminary safety data show no dose‑limiting toxicities, ICANS or significant CRS in the first three dose cohorts.

Lira-cel continues to exhibit positive survival data in ongoing Phase 1 clinical trial. SAN JOSE, Calif., April 22, 2026/ PRNewswire/-- Anixa Biosciences, Inc., a biotechnology company focused on the treatment and prevention of cancer, today announced that Cheryl Cox, MHA, Operations Director of the Cell Therapies and Gene Expression Engineering Facility at...

Anixa (NASDAQ: ANIX) announced that Dr. Robert Wenham of Moffitt Cancer Center will present an update on the company’s Phase 1 ovarian cancer CAR-T trial (lira-cel) at the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, April 10–13, 2026 in San Juan, Puerto Rico.The presentation will cover the trial design, objectives, and current status of the autologous T-cell therapy targeting FSHR in recurrent ovarian cancer.

Breast cancer vaccine presentation includes final Phase 1 data showing all major primary endpoints were met and protocol-defined immune responses in 74% of participants Ovarian cancer CAR-T therapy, lira-cel, presentation highlights positive survival observations from ongoing Phase 1...

Ovarian cancer CAR-T therapy, lira-cel, presentation to highlight positive survival observations from ongoing Phase 1 clinical trial Breast cancer vaccine presentation to include final Phase 1 data showing all major primary endpoints were met and protocol-defined immune responses in 74%...

Multiple patients have survived substantially beyond expected median survival, including one patient who survived 28 months and several patients who remain alive with continued follow-up Lira-cel clinical trial featured in presentation at the International Society for Cell & Gene Therapy...

Lira-cel continues to exhibit positive survival data in ongoing Phase 1 clinical trial SAN JOSE, Calif., April 22, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today...